ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call Scheduled for August 11, 2021 at 4:30 p.m. ET Conference Call Scheduled for August 11, 2021 at 4:30 p.m. ET

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adma Biologics (ADMA) Report Negative Q2 Earnings? What You Should Know

Canopy Growth

Hewlett Packard

Kirkland's

Zoom Video

Some of the stocks that may grab investor focus today are: Wall Street expects Hewlett Packard Enterprise Co (NYSE: HPE) to post quarterly earnings at $0.42 per share on revenue of $6.62 billion after the closing bell. Hewlett Packard Enterprise shares fell 2.3% to close at $15.96 on Friday.

5 Stocks To Watch For June 1, 2021

ADMA delivered another great quarter and is poised to experience revenue growth and margin expansion and has a path to profitability.

ADMA Biologics: Getting Unstuck Between A Rock And A Hard Place

ADMA Biologics Inc. (ADMA) CEO Adam Grossman on Q1 2021 Results - Earnings Call Transcript

Shares of ADMA Biologics (NASDAQ:ADMA) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 38.46% over the past year to ($0.16), which beat the estimate of ($0.17).

Recap: ADMA Biologics Q1 Earnings

Achieved First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020

ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments

On Wednesday, May 12, ADMA Biologics (NASDAQ:ADMA) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

ADMA Biologics Earnings Preview

ADMA Biologics (ADMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why ADMA Biologics (ADMA) Might Surprise This Earnings Season

Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET

ADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021

Today, ADMA stock is a big mover as the company announced a very bullish FDA approval allowing the company to scale its core product. The post ADMA Stock: The Big FDA News Boosting ADMA Biologics Today appeared first on InvestorPlace.

ADMA Stock: The Big FDA News Boosting ADMA Biologics Today

Will Adma Biologics (ADMA) Report Negative Q1 Earnings? What You Should Know

Boxlight

Verastem

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Are Back; Here's 3 to Watch Right Now

The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool to manufacture Intravenous Immune Globulin (IVIG). The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plant's total processing capacity from 400,000 liters to an anticipated peak throughput of up to 600,000 liters.

ADMA Biologics Shares Jump On Increased Manufacturing Capacity For Intravenous Immune Globulin

The stock price of ADMA Biologics Inc (NASDAQ: ADMA) increased by over 20% pre-market. This is why it happened.

ADMA Stock: Over 20% Increase Pre-Market Explanation

After a painful two months, shareholders of ADMA Biologics (NASDAQ:ADMA) may finally have something the be happy about. The downtrend in the stock that began in February has ended.

ADMA Biologics Breaks Downtrend And May Rally

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting

ADMA Biologics recently reported a mixed Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure. The ongoing pandemic has disrupted the industry; however, ADMA was able to report record revenue and expects to report quarter-over-quarter revenue growth.

ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth

ADMA continues to execute and delivered another great quarter. ADMA has improved its guidance with respect to profitability and plasma center developments.

ADMA Biologics: Continuing To Execute

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2020 Results - Earnings Call Transcript

Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019

ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Plasma Summit being held on Thursday, March 11, 2021, at 11:20 a.m. ET.

ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit

Atea Pharmaceuticals

BioNTech SE

Lexicon Pharmaceuticals

Moderna

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for ADMA Biologics Stock (ADMA)